

September 18, 2025

To  
The Listing Department,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
**Scrip Symbol: COHANCE**

To  
The Department of Corporate Services,  
BSE Limited  
25th floor, P. J. Towers,  
Dalal Street, Mumbai – 400 001  
**Scrip Code – 543064**

Dear Sir/Madam,

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – clarification on reported news in electronic media.**

This is in reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) regarding reported news in electronic media, <https://x.com/CNBCTV18News/status/1968556128444531120> & <https://youtu.be/dwiwfb5UaZE?si=ZL1YWgM0VU1Qeo-9>, amongst others, on September 18, 2025, with respect to disclosure to the stock exchanges made by the Company on August 13, 2025 in relation to USFDA inspection.

In this connection, we would like to inform that the Company *vide* intimation dated August 13, 2025, made a disclosure regarding completion of inspection by the USFDA at our Finished Dosage Formulations Manufacturing Facility (FDF Unit-I) located in Nacharam, Hyderabad, where we have received Form 483 with 6 (six) observations.

In view of the reported news in the aforesaid electronic media analysing the Form 483 observations, we wish to clarify that the Company has submitted a comprehensive Corrective and Preventive Action (CAPA) plan within the stipulated timeframe. We are actively engaging with the USFDA and remain committed to ensuring the highest standards of quality and compliance across all our manufacturing facilities.

We would like to highlight that in FY2025, US revenues from this facility contributed less than 2% of consolidated revenues, with related EBITDA contribution below 1%, indicating no material impact.

We would like to inform that we remain committed to maintaining the highest standards of quality and regulatory compliance in all our operations and will continue to ensure the manufacture and supply of high-quality pharmaceutical products for global markets.

This is for your information and record.

Thanking you.

Yours faithfully,  
For **Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

**Kundan Kumar Jha**  
*Company Secretary, Compliance Officer and Head-Legal*

---

**Cohance Lifesciences Limited**  
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad  
Knowledge City, TSIC, Raidurg, Hyderabad – 500081, Telangana, India.  
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road,  
Chakala, Andheri East, Chakala MIDC, Mumbai – 400093, Maharashtra, India.  
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | Company Email: [info@suvenpharm.com](mailto:info@suvenpharm.com)

